BioStock published an article on 16 March 2020 about sepsis and covid-19, which can be read in full below. A new study published in The Lancet shows that sepsis was the most common complication in more than half of...
Read MoreAptahem had planned to participate in both BIO Europe Spring and ISICEM during March, but one has been cancelled and the other postponed for six months due to the risk of spreading the Corona virus. The meetings that Aptahem...
Read MoreBioStock published an article on 4 March 2020 about Aptahem, which can be read in full below. Aptahem has been listed as a member of the American MTEC, a consortium that cooperates with the U.S. Army Medical Research and...
Read MoreAptahem (publ) today announced that the company now enters a consortium together with Örebro University, the pharmaceutical development company AnaMar and Dalhousie University in Canada. The newly established consortium aims to evaluate new strategies to reduce inflammation, thrombosis and...
Read MoreAptahem (publ) today announce positive final results from the exploratory sepsis study with non human primates, the NHP study. The new preclinical results continue to support Apta-1’s multifunctional drug candidate potential within the treatment of sepsis. The completed comprehensive...
Read MoreAptahem (publ) announced today that a presentation entitled “Apta-1, a novel RNA aptamer, improves outcome in an animal model of sepsis” will be held at the World Congress of Intensive Care in Melbourne, Australia, October 14-18, 2019. This conference...
Read MoreAptahem (publ) announced today that the company has signed an agreement with a GMP-certified (Good Manufacturing Practice) contract manufacturer, LGC Group. LGC Group will manufacture the company’s lead candidate, Apta-1, for the concluding toxicological studies and the production is...
Read MoreAptahem (publ), a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved, announces today that the cooperation with the Seattle Children’s Hospital has now generated the...
Read MoreAptahem today informs that the company’s latest patent application has been made public. The patent application, which is an international PCT application*, is a merger of two previous Europe applications with the priority date 3 October 2017. The patent...
Read MoreAptahem (publ) announced today that Dr. Anders Bylock, Chief Medical Officer (CMO), is taking on another part-time position effective immediately. Dr Bylock engagement with the company as CMO as well as chairman of the scientific advisory board is unchanged...
Read More